Sabby Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sabby Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,791	Closed	-$4.52M	–	354
2016 Q4	$4.52M	Buy	2,791 +2,328	+503%	+$42.2K	0.26%	57
2016 Q3	$839K	Hold	463	–	–	0.03%	197
2016 Q2	$763K	Buy	463 +73	+19%	+$1.18K	0.04%	185
2016 Q1	$646K	Buy	+390	New	+$6.82K	0.03%	191
2015 Q4	–	Sell	-1,658	Closed	-$3.29M	–	404
2015 Q3	$3.29M	Buy	+1,658	New	+$52.4K	0.14%	114
2015 Q1	–	Sell	-331	Closed	-$427	–	338
2014 Q4	$427	Buy	331 +90	+37%	+$1.13K	0.01%	194
2014 Q3	$296	Buy	241 +22	+10%	+$256	0.01%	209
2014 Q2	$346K	Hold	219	–	–	0.01%	203
2014 Q1	$331K	Buy	219 +108	+97%	+$1.22K	0.02%	193
2013 Q4	$85K	Buy	+111	New	+$599	0.01%	201

Other funds holding HZNP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sabby Management's HZNP Position: Q4 2015 in Review

Sabby Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 164,658 shares — an estimated $3.26M sold.

Sabby Management first reported a position in HZNP in Q3 2015 and held it in 1 quarter. The position peaked at $3.26M in Q3 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

Sabby Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
Sabby Management sold 164,658 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $3.26M.
Sabby Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 1 quarter.
Sabby Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.26M in Q3 2015.
202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.